Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual-pathway inhibition trained immunity study in coronary artery disease
NL-OMON50625Phase 4Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Mar 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rivaroxaban and aspirin in coronary arteriosclerosis, sponsored by Radboud University Medical Center. Started Mar 2022; status: active, not recruiting.
02
Drugs
rivaroxabanaspirin
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON50625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50625.